Outcomes of concurrent thoracic radiation with chemotherapy for EGFR wild-type local advanced non small cell lung cancer with COPD

doi:10.3877/cma.j.issn.1674-6902.2017.05.011

Abstract

Abstract:

Objective

To explore the recent therapeutic effect and adverse reactions of chemoradiation for epidermal growth factor receptor(EGFR) wild-type LA-non-small cell lung cancer(NSCLC) patients with chronic obstructive pulmonary disease(COPD) and atelectasis.

Methods

42 patients receive hypofractionation Intensity-modulated radiotherapy, 5 Gy/ fraction, three times/week, total dose 50-60Gy/10-12fractions, Concurrent chemotherapy with etoposide 50 mg/m² on days1 to 5 and cisplatin on days 1 to 5(total 70 mg/m²)every 4 weeks for two cycles.

Result

After treatment, 42 patients complete remission(CR) 6 cases(14.3%), partial remission(PR) 31 cases(73.8%), stable disease(SD) 5 cases(11.9%), progressive disease(PD) 0 case; Toxic effects mainly for radioactive pneumonia, of which the 0 level 16 cases (38.1%), Ⅰ-Ⅱ level 21 cases (50%), Ⅲ level 5 cases (12%).

Conclusion

hypofractionation Intensity-modulated radiotherapy Concurrent EP chemotherapy is effective and well-tolerated for EGFR wild-type LA-NSCLC patients with COPD and atelectasis.

Key words: Chemoradiation, EGFR wild-type, Local advanced, Non-small cell lung cancer, Chronic obstructive pulmonary disease

Jianfei Du, Jie Chang, Lichun Cui, Xuan Wang, Shengqiang Dang, Shuangyan Zhang, Shuanying Yang. Outcomes of concurrent thoracic radiation with chemotherapy for EGFR wild-type local advanced non small cell lung cancer with COPD[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(05): 559-563.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.05.011

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I05/559

Figures/Tables 3

References 23

1	钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
2	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
3	任成山，钱桂生. 慢性阻塞性肺疾病发病机制研究现状与展望[J/CD]. 中华肺部疾病杂志(电子版), 2009, 2(2): 104-115.
4	Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014[J]. Arch Bronconeumol, 2014, 50 Suppl 1: 1-16.
5	任成山，白莉，钱桂生. 慢性阻塞性肺疾病合并肺癌临床特征及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(2): 137-142.
6	Steuer CE, Behera M, Ernani V, et al. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage Ⅲ Non-Small-Cell Lung Cancer: A Systematic Review[J]. JAMA Oncol, 2017, 3(8): 1120-1129.
7	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
8	Yin P, Wang H, Vos T, et al. A Subnational analysis of mortality and prevalence of COPD in China from 1990 to 2013[J]. Chest, 2016, 150(6): 1269-1280.
9	Durham AL, Adcock IM. The relationship between COPD and lung cancer [J]. Lung Cancer, 2015, 90(2): 121-127.
10	Hecht SS, Carmella SG, Murphy SE, et al. Tobacco smoke toxicant and carcinogen biomarkers and lung cancer susceptibility in smokers[J] J Thorac Oncol, 2016, 11(2): S7-S8.
11	Kohansal R, Martinez-Camblor P, Agustí A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort [J]. Am J Respir Crit Care Med, 2009, 180(1): 3-10.
12	Tockman MS, Anthonisen NR, Wright EC, et al. Airways obstruction and the risk for lung cancer[J]. Ann Intern Med, 1987, 106(4): 512-518.
13	Yang P, Allen MS, Aubry MC, et al. Clinical features of 5，628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003[J]. Chest, 2005, 128(1): 452-462.
14	石远凯，孙燕，于金明，等. 中国晚期原发性肺癌诊治专家共识(2016年版)[J]. 中国肺癌杂志，2016, 19(1): 1-15.
15	Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights：non-small cell lung cancer, version 4.2016[J]. J Natl Compr Canc Netw, 2016, 14(3): 255-264.
16	Baumann M, Appold S, Petersen C, et al. Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer [J]. Lung cancer, 2001, 33 Suppl 1: S35-S45.
17	Liang J, Bi N, Wu S, et al. Etoposide and Cisplatin vs Paclitaxel and Carboplatin With Concurrent Thoracic Radiotherapy in Unresectable Stage Ⅲ Non-Small Cell Lung Cancer: A Multicenter Randomized Phase Ⅲ Trial[J]. Ann Oncol, 2017, 28(4): 777-783.
18	Sekine Y, Hata A, Koh E, et al. Lung carcinogenesis from chronic obstructive pulmonary disease: characteristics of lung cancer from COPD and contribution of signal transducers and lung stem cells in the inflammatory microenvironment[J]. Gen Thorac Cardiovasc Surg, 2014, 62(7): 415-421.
19	Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis[J]. Int J Radiat Oncol Biol Phys, 2013, 85(2): 444-450.
20	Dang J, Li G, Lu X, et al. Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy [J]. J Cancer Res Clin Oncol, 2010, 136(8): 1169-1178.
21	Shi A, Zhu G, Wu H, et al. Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy[J]. Radiat Oncol, 2010, 5(1): 35.
22	Warner A, Dahele M, Hu B, et al. Factors associated with early mortality in patients treated with concurrent chemoradiation therapy for locally advanced non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 94(3): 612-620.
23	Kim M, Lee J, Ha B, et al. Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer [J]. Radiat Oncol J, 2011, 29(3): 181-190.

疗　效	≤5 cm(n＝25)		>5 cm(n＝17)		合计(n＝42)
疗　效	例数	构成比(%)	例数	构成比(%)	例数	构成比(%)
CR	3	12.00	3	17.65	6	14.29
PR	21	84.00	10	58.82	31	73.81
SD	1	4.00	4	23.53	5	11.90
PD	0	0.00	0	0.00	0	0.00

疗　效	≤5 cm(n＝25)		>5 cm(n＝17)		合计(n＝42)
疗　效	例数	构成比(%)	例数	构成比(%)	例数	构成比(%)
CR	3	12.00	3	17.65	6	14.29
PR	21	84.00	10	58.82	31	73.81
SD	1	4.00	4	23.53	5	11.90
PD	0	0.00	0	0.00	0	0.00

组　别	例数	FEV₁	FEV₁/FVC	DLCO	VC	FVC
治疗前	42	48.31±7.25	50.16±8.56	53.02±6.72	53.6±6.2	51.45±7.12
治疗后	42	67.24±6.32	66.21±5.23	67.23±7.01	67.4±6.45	66.82±5.85
P值	?	<0.05	<0.05	<0.05	<0.05	<0.05

组　别	例数	FEV₁	FEV₁/FVC	DLCO	VC	FVC
治疗前	42	48.31±7.25	50.16±8.56	53.02±6.72	53.6±6.2	51.45±7.12
治疗后	42	67.24±6.32	66.21±5.23	67.23±7.01	67.4±6.45	66.82±5.85
P值	?	<0.05	<0.05	<0.05	<0.05	<0.05

级　别	例数	百分比(%)
0级	16	38.1
Ⅰ级	12	28.6
Ⅱ级	9	21.4
Ⅲ级	5	12
Ⅳ级	0	0

Please choose a citation manager

Content to export